US FTC settles case against anesthesia company

• The alleged rollup involved over a dozen anesthesiology practices, 1,000 doctors, and 750 nurses across Texas
• Private equity firm Welsh, Carson, Anderson & Stowe, which created USAP, was initially sued but dropped from the case after winning a dismissal bid
• Settlement terms are confidential to facilitate USAP's negotiations; if USAP fails to fully execute the settlement, the FTC will resume its case

Summary

The U.S. Federal Trade Commission (FTC) has reached a settlement with USAP, a private equity-backed anesthesiology company accused of anticompetitive practices in Texas. The case represents a significant enforcement action against private equity rollups in the healthcare sector.

Key Details:

The FTC alleged that USAP, created by private equity firm Welsh, Carson, Anderson & Stowe, acquired over a dozen anesthesiology practices employing approximately 1,000 doctors and 750 nurses to consolidate the market and raise prices. While Welsh, Carson, Anderson & Stowe was initially sued, the firm successfully won dismissal of claims against it.

Settlement Terms:

Settlement details remain confidential to facilitate USAP's negotiations. The FTC stated the agreement will "restore a competitive market structure" and align with the agency's longstanding settlement practices. If USAP fails to fully execute the settlement terms, the FTC will resume litigation.

Market Implications:

This case marks a major antitrust action against private equity rollups—strategies where firms acquire multiple small businesses to reduce industry competition. The settlement will be closely watched by private equity firms as a precedent for regulatory scrutiny of consolidation strategies, particularly in healthcare.

Under the Trump administration, the FTC has prioritized healthcare enforcement while demonstrating willingness to settle cases on acceptable terms. The case signals continued regulatory pressure on private equity consolidation practices that potentially harm competition and increase consumer costs, though specific remedies and their impact on the industry remain unclear pending public disclosure of settlement terms.